SyntekaBio, Inc.
Financials
Valuation Metrics
SyntekaBio, Inc.'s Market Cap is ₩242B. At end of 2025 it was ₩945B. Ranked #2154 of 2,405 in KR market (top 90%), #1398 of 1,627 on KOSDAQ (top 86%), #87 of 94 in Health Care Equipment & Services (top 93%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 24.19B KRW | KR#2,154/2,405 Sec#87/94 |
| Revenue | 3.09B KRW | KR#2,354/2,405 Sec#92/94 |
| Net Income | -11.96B KRW | KR—/2,405 Sec—/94 |
| Total Assets | 37.98B KRW | KR#2,284/2,405 Sec#82/94 |
| Net Assets | 25.93B KRW | KR#2,207/2,405 Sec#81/94 |
| Employees | 61 | KR#1,952/2,405 Sec#80/94 |
| Value | ||
| P/B | 0.93x | KR#1,472/2,405 Sec#38/94 |
| P/S | 7.84x | KR#2,249/2,405 Sec#80/94 |
| FCF Yield | -44.08% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | -46.12% | KR#2,254/2,405 Sec#84/94 |
| ROA | -31.48% | KR#2,311/2,405 Sec#87/94 |
| Op. Margin | -339.67% | KR#2,335/2,405 Sec#89/94 |
| Revenue Growth | 132.30% | KR#63/2,405 Sec#5/94 |
| Financial Health | ||
| Debt Ratio | 46.49% | KR#910/2,405 Sec#50/94 |
| Total Debt | 6.36B KRW | KR#1,733/2,405 Sec#59/94 |
| FCF | -10.66B KRW | KR#1,715/2,405 Sec#63/94 |
| Cash | 7.46B KRW | KR#1,842/2,405 Sec#62/94 |
| Current Ratio | 0.97x | KR#1,744/2,405 Sec#78/94 |
| Performance | ||
| 1Y Return | -70.10% | KR#2,276/2,405 Sec#90/94 |
| 1M Return | -21.25% | KR#1,939/2,405 Sec#83/94 |
| From 52W High | -85.23% | KR#2,361/2,405 Sec#92/94 |
| 1Y MDD | -83.10% | KR#2,320/2,405 Sec#90/94 |
| Trading | ||
| Volume | 200,771 shares | KR#369/2,405 Sec#15/94 |
| Trading Value | 200.6M KRW | KR#1,128/2,405 Sec#43/94 |
| Foreign Own. | 1.00% | KR#2,027/2,405 Sec#78/94 |
| Per Share | ||
| EPS | -493 KRW | KR—/2,405 Sec—/94 |
| BPS | 1,069 KRW | KR#2,287/2,405 Sec#87/94 |
Company Info
Syntekabio, a bio venture established in 2009, became a research institute company in 2014, receiving dedicated supercomputing technology for genetic testing from ETRI. It offers AI new drug development platform services and a genomic big data platform, including NGS-ARS® precision medicine services, on a cloud basis. Leveraging an AI platform that integrates supercomputing and genomic big data technologies, Syntekabio focuses on innovating the new drug development process and developing new paradigm treatments. The company is headquartered in Yuseong-gu, Daejeon Metropolitan City.